Find Maralixibat Chloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lopixibat chloride, 228113-66-4, Lum-001, Maralixibat chloride [usan], Lum001, Maralixibat (chloride)
Molecular Formula
C40H56ClN3O4S
Molecular Weight
710.4  g/mol
InChI Key
POMVPJBWDDJCMP-RUKDTIIFSA-M
FDA UNII
V78M04F0XC

Maralixibat Chloride
1 2D Structure

Maralixibat Chloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-16-benzothiepin-4-ol;chloride
2.1.2 InChI
InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1
2.1.3 InChI Key
POMVPJBWDDJCMP-RUKDTIIFSA-M
2.1.4 Canonical SMILES
CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
2.1.5 Isomeric SMILES
CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
2.2 Other Identifiers
2.2.1 UNII
V78M04F0XC
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (4r,5r)-5-(4-((4-(4-aza-1-azoniabicyclo(2.2.2)octan-1-ylmethyl)phenyl)methoxy)phenyl)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-16-benzothiepin-4-ol

2. Livmarli

3. Maralixibat

2.3.2 Depositor-Supplied Synonyms

1. Lopixibat Chloride

2. 228113-66-4

3. Lum-001

4. Maralixibat Chloride [usan]

5. Lum001

6. Maralixibat (chloride)

7. V78m04f0xc

8. 228113-66-4 (chloride)

9. Livmarli

10. Lum 001

11. 4-aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-, Chloride (1:1)

12. Chembl17879

13. (4r,5r)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1lambda6-benzothiepin-4-ol;chloride

14. 1-(4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium Chloride

15. Lopixibat Chloride [inn]

16. Unii-v78m04f0xc

17. Shp 625

18. Schembl6336189

19. Shp625

20. Maralixibat Chloride (usan/inn)

21. Dtxsid701337104

22. Maralixibat Chloride [inn]

23. Maralixibat Chloride [who-dd]

24. Hy-16747

25. Maralixibat Chloride [orange Book]

26. Cs-0012347

27. D10952

28. Q27291628

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 710.4 g/mol
Molecular Formula C40H56ClN3O4S
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count13
Exact Mass709.3680061 g/mol
Monoisotopic Mass709.3680061 g/mol
Topological Polar Surface Area78.5 Ų
Heavy Atom Count49
Formal Charge0
Complexity1080
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

Treatment of Progressive Familial Intrahepatic Cholestasis


Treatment of Alagille syndrome


Treatment of biliary atresia


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Pharmacological Classes
Ileal Bile Acid Transporter Inhibitors [MoA]; Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]; Ileal Bile Acid Transporter Inhibitor [EPC]
5.2 ATC Code

A - Alimentary tract and metabolism

A05 - Bile and liver therapy

A05A - Bile therapy

A05AX - Other drugs for bile therapy

A05AX04 - Maralixibat chloride


API SUPPLIERS

read-more
read-more

01

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner

02

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Biophore

03

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCOPE Summit
Not Confirmed
arrow

Apicore

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SCOPE Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

04

Zhejiang Ausun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCOPE Summit
Not Confirmed
arrow

Zhejiang Ausun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SCOPE Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2025-09-03

Pay. Date : 2025-07-09

DMF Number : 42238

Submission : 2025-07-29

Status : Active

Type : II

Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2025-08-22

Pay. Date : 2025-07-14

DMF Number : 41809

Submission : 2025-04-30

Status : Active

Type : II

Biophore

03

SCOPE Summit
Not Confirmed

03

SCOPE Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-07-25

Pay. Date : 2025-06-18

DMF Number : 41516

Submission : 2025-04-24

Status : Active

Type : II

blank

04

SCOPE Summit
Not Confirmed

04

SCOPE Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-06-23

Pay. Date : 2025-03-21

DMF Number : 41496

Submission : 2025-03-27

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

SCOPE Summit
Not Confirmed
arrow
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

NDC Package Code : 42973-381

Start Marketing Date : 2025-08-06

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

SCOPE Summit
Not Confirmed
arrow
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

NDC Package Code : 76397-040

Start Marketing Date : 2025-03-17

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Maralixibat Chloride

About the Company : Honour is a leading global CDMO and trusted manufacturer of specialty chemicals and ingredients, with seven world-class facilities meeting global safety and quality standards. Thro...

Honour is a leading global CDMO and trusted manufacturer of specialty chemicals and ingredients, with seven world-class facilities meeting global safety and quality standards. Through Honour Synthesis and Honour Specialty, it delivers innovative solutions leveraging chemistry expertise. Its team of over 2,500 professionals partners with pharmaceutical, biotech, and specialty industries worldwide to develop practical, scalable solutions. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Maralixibat Chloride

About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...

Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&D center of 400 scientists, the company is a leading global API player. Biophore ranks among the top US DMF filers, holds 150+ patents and maintains a strong compliance record with major regulatory agencies. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Biophore
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"BULK DRUG : MARALIXIBAT CHLORIDE, CAS NO- 228113-66-4","address":"PLOT 121 GIDC MAKARPURA INDL.ESTATE","city":"VADODARA","supplier":"APICORE PHARMACEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LONDON - HEATHROW","customer":"LM MANUFACTURING LTD","customerCountry":"UNITED KINGDOM","quantity":"1.65","actualQuantity":"1.65","unit":"KGS","unitRateFc":"251363.6","totalValueFC":"409009.5","currency":"USD","unitRateINR":21062500,"date":"24-Dec-2024","totalValueINR":"34753125","totalValueInUsd":"409009.5","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"6717860","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 121 GIDC MAKARPURA INDL.ESTATE, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1735669800,"product":"BULK DRUG : MARALIXIBAT CHLORIDE, CAS NO- 228113-66-4","address":"PLOT 121 GIDC MAKARPURA INDL.ESTATE","city":"VADODARA","supplier":"APICORE PHARMACEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LONDON - HEATHROW","customer":"LM MANUFACTURING LTD","customerCountry":"UNITED KINGDOM","quantity":"2.35","actualQuantity":"2.35","unit":"KGS","unitRateFc":"251018.3","totalValueFC":"574015.3","currency":"USD","unitRateINR":21062500,"date":"01-Jan-2025","totalValueINR":"49496875","totalValueInUsd":"574015.3","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"6943392","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 121 GIDC MAKARPURA INDL.ESTATE, VADODARA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1740594600,"product":"MARALIXIBAT CHLORIDE","address":"7-2-A2, GROUND FLOOR, HETERO,CORPO","city":"SANATHNAGAR,TELANGANA","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"ANNORA PHARMA PRIVATE LTD","customerCountry":"INDIA","quantity":"1.90","actualQuantity":"1.9","unit":"KGS","unitRateFc":"205128.2","totalValueFC":"393265.8","currency":"USD","unitRateINR":"18000000","date":"27-Feb-2025","totalValueINR":"34200000","totalValueInUsd":"393265.8","indian_port":"Vizag-HIPL SEZ","hs_no":"29349990","bill_no":"8587193","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"HETERO INFRASTRUCTURE SEZ LTD N.NARASAPURAM VILLAGE,NAKKAPALLY M SDNF India","customerAddress":"7-2-A2, GROUND FLOOR, HETERO,CORPO"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1758133800,"product":"MARALIXIBAT CHLORIDE","address":"7-2-A2, GROUND FLOOR, HETERO,CORPO","city":"SANATHNAGAR,TELANGANA","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"ANNORA PHARMA PRIVATE LTD","customerCountry":"INDIA","quantity":"5.15","actualQuantity":"5.15","unit":"KGS","unitRateFc":"202247.2","totalValueFC":"1050198.3","currency":"USD","unitRateINR":"18000000","date":"18-Sep-2025","totalValueINR":"92700000","totalValueInUsd":"1050198.3","indian_port":"Vizag-HIPL SEZ","hs_no":"29349990","bill_no":"4573650","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"HETERO INFRASTRUCTURE SEZ LTD N.NARASAPURAM VILLAGE,NAKKAPALLY M SDNF India","customerAddress":"7-2-A2, GROUND FLOOR, HETERO,CORPO"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1759170600,"product":"MARALIXIBAT CHLORIDE","address":"7-2-A2, GROUND FLOOR, HETERO,CORPO","city":"SANATHNAGAR,TELANGANA","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"ANNORA PHARMA PRIVATE LTD","customerCountry":"INDIA","quantity":"3.93","actualQuantity":"3.93","unit":"KGS","unitRateFc":"202588.6","totalValueFC":"801413.5","currency":"USD","unitRateINR":"18000000","date":"30-Sep-2025","totalValueINR":"70740000","totalValueInUsd":"801413.5","indian_port":"Vizag-HIPL SEZ","hs_no":"29349990","bill_no":"4822822","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"HETERO INFRASTRUCTURE SEZ LTD N.NARASAPURAM VILLAGE,NAKKAPALLY M SDNF India","customerAddress":"7-2-A2, GROUND FLOOR, HETERO,CORPO"}]
24-Dec-2024
30-Sep-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Livmarli (maralixibat chloride) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 3 month of age and older.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 14, 2025

blank

01

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat chloride) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 3 month of age and older.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 14, 2025

blank

Details:

Livmarli (maralixibat chloride) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2025

blank

02

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat chloride) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 27, 2025

blank

Details:

Under the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Abacus Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 09, 2024

blank

03

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Under the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Undisclosed

September 09, 2024

blank

Details:

Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor, approved for PFIC patients 12 months and older in higher concentrations.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 25, 2024

blank

04

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor, approved for PFIC patients 12 months and older in higher concentrations.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 25, 2024

blank

Details:

LIVMARLI® (maralixibat) oral solution is a minimally absorbed IBAT inhibitor, approved for treating of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 08, 2024

blank

05

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : LIVMARLI® (maralixibat) oral solution is a minimally absorbed IBAT inhibitor, approved for treating of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 08, 2024

blank

Details:

Livmarli (maralixibat) is an oral IBAT inhibitor, which is under clinical development for the treatment of Progressive Familial Intrahepatic Cholestasis.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Livmarli

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 31, 2024

blank

06

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat) is an oral IBAT inhibitor, which is under clinical development for the treatment of Progressive Familial Intrahepatic Cholestasis.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 31, 2024

blank

Details:

LIVMARLI® (maralixibat), an IBAT inhibitor, has FDA approval for cholestatic pruritus in progressive familial intrahepatic cholestasis.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 13, 2024

blank

07

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : LIVMARLI® (maralixibat), an IBAT inhibitor, has FDA approval for cholestatic pruritus in progressive familial intrahepatic cholestasis.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 13, 2024

blank

Details:

Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor, which is under phase 2 clinical development for the treatment of Biliary Atresia.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2023

blank

08

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor, which is under phase 2 clinical development for the treatment of Biliary Atresia.

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2023

blank

Details:

Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 17, 2023

blank

09

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholest...

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 17, 2023

blank

Details:

Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.


Lead Product(s): Maralixibat Chloride,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Livmarli

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 16, 2023

blank

10

SCOPE Summit
Not Confirmed
SCOPE Summit
Not Confirmed

Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholest...

Product Name : Livmarli

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 16, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions
The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 

Impressions: 3332

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

#PharmaFlow by PHARMACOMPASS
13 Nov 2025

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 12350267

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-3973

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-26

blank

02

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 10512657

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-4186

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-26

blank

03

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 12296050

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 219485

Patent Use Code : U-4187

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2043-10-05

blank

04

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 11260053

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-4187

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-05-26

blank

05

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 12350267

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-3973

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-26

blank

06

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 10512657

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-4186

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-26

blank

07

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 11497745

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-4187

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2040-02-12

blank

08

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 12296050

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 219485

Patent Use Code : U-4187

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2043-10-05

blank

09

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 11260053

Drug Substance Claim :

Drug Product Claim :

Application Number : 219485

Patent Use Code : U-4187

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-05-26

blank

10

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

US Patent Number : 11229647

Drug Substance Claim :

Drug Product Claim :

Application Number : 214662

Patent Use Code : U-3974

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2040-02-12

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : I-938

Exclusivity Expiration Date : 2027-03-13

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

02

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : NCE

Exclusivity Expiration Date : 2026-09-29

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

03

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : NPP

Exclusivity Expiration Date : 2026-03-13

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

04

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE-379

Exclusivity Expiration Date : 2028-09-29

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

05

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE-429

Exclusivity Expiration Date : 2030-03-13

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

06

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE-471

Exclusivity Expiration Date : 2031-03-13

Application Number : 214662

Product Number : 1

Exclusivity Details :

blank

07

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : NCE

Exclusivity Expiration Date : 2026-09-29

Application Number : 214662

Product Number : 2

Exclusivity Details :

blank

08

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE*

Exclusivity Expiration Date : 2030-03-13

Application Number : 214662

Product Number : 2

Exclusivity Details :

blank

09

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE*

Exclusivity Expiration Date : 2028-09-29

Application Number : 214662

Product Number : 2

Exclusivity Details :

blank

10

arrow
SCOPE Summit
Not Confirmed

MIRUM

U.S.A
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Exclusivity Code : ODE*

Exclusivity Expiration Date : 2031-03-13

Application Number : 214662

Product Number : 2

Exclusivity Details :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

read-more
read-more

01

Gowling WLG (Canada) LLP

arrow
SCOPE Summit
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Brand Name : LIVMARLI

Patent Number : 2852957

Filing Date : 2012-10-26

Strength per Unit : 9.5mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-10-26

Date Granted : 2020-08-04

blank

02

Gowling WLG (Canada) LLP

arrow
SCOPE Summit
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
SCOPE Summit
Not Confirmed

MARALIXIBAT CHLORIDE

Brand Name : LIVMARLI

Patent Number : 2853285

Filing Date : 2012-10-26

Strength per Unit : 9.5mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-10-26

Date Granted : 2020-05-05

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 228113-66-4 / Maralixibat Chloride API manufacturers, exporters & distributors?

Maralixibat Chloride manufacturers, exporters & distributors 1

84

PharmaCompass offers a list of Maralixibat Chloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Maralixibat Chloride manufacturer or Maralixibat Chloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Maralixibat Chloride manufacturer or Maralixibat Chloride supplier.

PharmaCompass also assists you with knowing the Maralixibat Chloride API Price utilized in the formulation of products. Maralixibat Chloride API Price is not always fixed or binding as the Maralixibat Chloride Price is obtained through a variety of data sources. The Maralixibat Chloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Maralixibat Chloride

Synonyms

Lopixibat chloride, 228113-66-4, Lum-001, Maralixibat chloride [usan], Lum001, Maralixibat (chloride)

Cas Number

228113-66-4

Unique Ingredient Identifier (UNII)

V78M04F0XC

Maralixibat Chloride Manufacturers

A Maralixibat Chloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maralixibat Chloride, including repackagers and relabelers. The FDA regulates Maralixibat Chloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maralixibat Chloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Maralixibat Chloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Maralixibat Chloride Suppliers

A Maralixibat Chloride supplier is an individual or a company that provides Maralixibat Chloride active pharmaceutical ingredient (API) or Maralixibat Chloride finished formulations upon request. The Maralixibat Chloride suppliers may include Maralixibat Chloride API manufacturers, exporters, distributors and traders.

click here to find a list of Maralixibat Chloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Maralixibat Chloride USDMF

A Maralixibat Chloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Maralixibat Chloride active pharmaceutical ingredient (API) in detail. Different forms of Maralixibat Chloride DMFs exist exist since differing nations have different regulations, such as Maralixibat Chloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Maralixibat Chloride DMF submitted to regulatory agencies in the US is known as a USDMF. Maralixibat Chloride USDMF includes data on Maralixibat Chloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Maralixibat Chloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Maralixibat Chloride suppliers with USDMF on PharmaCompass.

Maralixibat Chloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maralixibat Chloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Maralixibat Chloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Maralixibat Chloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Maralixibat Chloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maralixibat Chloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Maralixibat Chloride suppliers with NDC on PharmaCompass.

Maralixibat Chloride GMP

Maralixibat Chloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Maralixibat Chloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maralixibat Chloride GMP manufacturer or Maralixibat Chloride GMP API supplier for your needs.

Maralixibat Chloride CoA

A Maralixibat Chloride CoA (Certificate of Analysis) is a formal document that attests to Maralixibat Chloride's compliance with Maralixibat Chloride specifications and serves as a tool for batch-level quality control.

Maralixibat Chloride CoA mostly includes findings from lab analyses of a specific batch. For each Maralixibat Chloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Maralixibat Chloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Maralixibat Chloride EP), Maralixibat Chloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maralixibat Chloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty